This week on Pharm5:
- ASHP Match Results
- Generic Symbicort Approved
- Lynparza reduces death 32% in HER2-neg, gBRCAm breast cancer
- Congress passes 340B protection
- 4th Pfizer COVID vaccine
Connect with us!
- Listen to our podcast: Pharm5
- Watch us on TikTok: @LizHearnPharmD
- Follow us on Twitter: @LizHearnPharmD
References:
- Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published January 6, 2022. Accessed March 16, 2022.
- Commissioner of the FDA approves first generic of Symbicort to treat asthma and COPD. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-symbicort-treat-asthma-and-copd?utm_campaign=%2BFDA%2BApproves%2BFirst%2BGeneric%2Bof%2BSymbicort%2Bto%2BTreat%2BAsthma%2Band%2BCOP&utm_medium=email&utm_source=govdelivery. Accessed March 17, 2022.
- Lynparza® (OLAPARIB) reduced risk of death by 32% in patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer in phase 3 olympia trial. Merck.com. https://www.merck.com/news/lynparza-olaparib-reduced-risk-of-death-by-32-in-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer-in-phase-3-olympia-trial/. Published March 17, 2022. Accessed March 17, 2022.
- Congress passes omnibus spending bill with 340B DSH protection, telehealth provisions. ASHP. https://www.ashp.org/news/2022/03/11/congress-passes-omnibus-spending-bill-340b-dsh-eligibility?loginreturnUrl=SSOCheckOnly. Published March 11, 2022. Accessed March 16, 2022.
- Pfizer and BioNTech submit for U.S. emergency use authorization of an additional booster dose of their COVID-19 vaccine for older adults. Pfizer. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization. Published March 15, 2022. Accessed March 16, 2022.
